Shay Capital’s Lexeo Therapeutics LXEO Stock Holding History

Shay Capital’s Portfolio LXEO Stock Details LXEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-43,296	Closed	-$150K	–	389
2025 Q1	$150K	Buy	+43,296	New	+$192K	0.02%	256

Other funds holding LXEO

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Shay Capital's LXEO Position: Q2 2025 in Review

Shay Capital sold out of Lexeo Therapeutics (LXEO) in Q2 2025, closing a stake of 43,296 shares — an estimated $150K sold.

Shay Capital first reported a position in LXEO in Q1 2025 and held it in 1 quarter. The position peaked at $150K in Q1 2025. 90 funds tracked by Wall St. Rank hold LXEO as of Q2 2025.

Shay Capital reported no remaining Lexeo Therapeutics position as of Q2 2025 after selling out during the quarter.
Shay Capital sold 43,296 Lexeo Therapeutics shares in Q2 2025, an estimated $150K.
Shay Capital first reported a position in Lexeo Therapeutics in Q1 2025 and held it in 1 quarter.
Shay Capital's Lexeo Therapeutics position peaked at $150K in Q1 2025.
90 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2025.

Based on Shay Capital's 13F filing for Q2 2025, filed 14 Aug 2025.